Intrinsiqq
OncoZenge AB logo

OncoZenge AB

ONCOZ.XSTO

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Capkr 36M
EPS-kr 2.03
P/E-0.11
P/FCF-1.49
EV/EBITDA-1.54
FCF Yield–
Div. Yield–
Net Debt/FCF-0.2x
OncoZenge AB intrinsic value
52-Week Range
€0.23€0.68

Profitability & Returns

Revenue (TTM)

kr 6M

Net Income (TTM)

-kr 26M

▼ -83.5% YoY

Op. Margin

-439.80%

ROIC

-96.21%

▼ -48.2pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-kr 24M

▼ -49.0% YoY

Op. Cash Flow (TTM)

-kr 24M

▼ -49.0% YoY

Net Debt

kr 4M

Cash & Equiv.

kr 4M

Continue Research

Peers

Biotechnology · Pick stocks to compare with ONCOZ.XSTO

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.08-10.74%40
NXTCL.XSTONextCell Pharma AB
€0.01-16.36%50
KDEV.XSTOKDventures AB
kr 0.15-37.39%25
BIOSGN.XSTOBiosergen AB
No recent price20
HEART.XSTOScandinavian Real Heart AB
€1.38-1.78%10
2CUREX.XSTO2cureX AB
No recent price10
APOTEA.XSTOApotea AB
€9.36+0.43%71
XVIVO.XSTOXVIVO Perfusion AB
kr 198.20-0.65%44

OncoZenge AB (ONCOZ.XSTO) in four numbers

Fair value (revenue)
€0.07
Price €0.23 is 210% above it.
Intrinsic Value
Quality score
0/100
Best check: share count change, 19.9%.
Quality
Dividend
None
No dividend in the company filings we hold.
Dividends
P/E
-0.11
Negative: a loss over the last twelve months. Price to free cash flow -1.49.
Financials

Questions about OncoZenge AB

Is OncoZenge AB (ONCOZ.XSTO) overvalued?

At €0.23, OncoZenge AB's price is 210% above the €0.07 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is OncoZenge AB's fair value?

Intrinsiqq's calculator puts OncoZenge AB's fair value at €0.07 a share. It grows revenue per share 5% a year for 5 years, applies an exit P/S of 2.5, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of €0.06. Every input can be changed on the Intrinsic Value tab.

Is OncoZenge AB a high-quality business?

OncoZenge AB scores 0 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is share count change at 19.9%. The Quality tab shows every check against its target.

Does OncoZenge AB (ONCOZ.XSTO) pay a dividend?

No. OncoZenge AB (ONCOZ.XSTO) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: company filings. Price: last close 6 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ONCOZ.XSTO

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.